ImmuCell Ownership
| ICCC Stock | USD 4.74 0.07 1.46% |
Shares in Circulation | First Issued 1989-03-31 | Previous Quarter 7.8 M | Current Value 7.8 M | Avarage Shares Outstanding 3.6 M | Quarterly Volatility 1.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
ImmuCell |
ImmuCell Stock Ownership Analysis
About 27.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.56. Some equities with similar Price to Book (P/B) outperform the market in the long run. ImmuCell has Price/Earnings (P/E) ratio of 195.0. The entity recorded a loss per share of 0.75. The firm had not issued any dividends in recent years. ImmuCell had 1:100 split on the 25th of July 1990. ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Immucell operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 64 people. To learn more about ImmuCell call Michael Brigham at 207 878 2770 or check out https://immucell.com.Besides selling stocks to institutional investors, ImmuCell also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different ImmuCell's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align ImmuCell's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
ImmuCell Quarterly Liabilities And Stockholders Equity |
|
ImmuCell Insider Trades History
About 27.0% of ImmuCell are currently held by insiders. Unlike ImmuCell's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against ImmuCell's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of ImmuCell's insider trades
ImmuCell Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ImmuCell is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ImmuCell backward and forwards among themselves. ImmuCell's institutional investor refers to the entity that pools money to purchase ImmuCell's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Strategic Investment Advisors Inc | 2023-12-31 | 31 K | Hightower Advisors, Llc | 2023-12-31 | 21.4 K | Prosperity Planning, Inc. | 2024-03-31 | 16 K | Blackrock Inc | 2023-12-31 | 15.5 K | Wealth Effects Llc | 2023-12-31 | 15.4 K | Citadel Advisors Llc | 2023-09-30 | 15 K | Mesirow Fin Investmt Mgmt Intl Equity | 2023-12-31 | 12.2 K | Essex Financial Services, Inc. | 2023-12-31 | 11 K | Mission Wealth Management, Llc | 2023-12-31 | 10 K | Vanguard Group Inc | 2023-12-31 | 206.6 K | Renaissance Technologies Corp | 2023-12-31 | 126.2 K |
ImmuCell Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ImmuCell insiders, such as employees or executives, is commonly permitted as long as it does not rely on ImmuCell's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ImmuCell insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
David Tomsche over three weeks ago Acquisition by David Tomsche of 485 shares of ImmuCell at 7.77 subject to Rule 16b-3 | ||
David Tomsche over three weeks ago Acquisition by David Tomsche of tradable shares of ImmuCell at 5.53 subject to Rule 16b-3 | ||
Michael Brigham over two months ago Acquisition by Michael Brigham of 47500 shares of ImmuCell at 1.7 subject to Rule 16b-3 | ||
David Tomsche over six months ago Disposition of 3100 shares by David Tomsche of ImmuCell subject to Rule 16b-3 | ||
David Tomsche over a year ago Disposition of 400 shares by David Tomsche of ImmuCell subject to Rule 16b-3 |
ImmuCell Corporate Filings
8K | 14th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 26th of April 2024 Other Reports | ViewVerify | |
| 10th of April 2024 Prospectus used primarily for registering securities for public sale. | ViewVerify | |
10K | 1st of April 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.Note that the ImmuCell information on this page should be used as a complementary analysis to other ImmuCell's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for ImmuCell Stock analysis
When running ImmuCell's price analysis, check to measure ImmuCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuCell is operating at the current time. Most of ImmuCell's value examination focuses on studying past and present price action to predict the probability of ImmuCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuCell's price. Additionally, you may evaluate how the addition of ImmuCell to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is ImmuCell's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.75) | Revenue Per Share 2.255 | Quarterly Revenue Growth 0.303 | Return On Assets (0.07) |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.